NASDAQ:MDNA

Medicenna Therapeutics Stock Forecast, Price & News

$3.41

+0.17 (+5.25 %)

(As of 05/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$3.23

▼

$3.45

50-Day Range

$3.24

▼

$4.28

52-Week Range

$3.14

▼

$6.84

Volume44,331 shs

Average Volume206,347 shs

Market Capitalization$182.60 million

P/E RatioN/A

Dividend YieldN/A

Beta1.39

30 days | 90 days | 365 days | Advanced Chart

Receive MDNA News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

About Medicenna Therapeutics

Medicenna Therapeutics Corp., a clinical stage immunotherapy company, develops and commercializes Empowered Cytokines (EC) and Superkines for the treatment of cancer. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that is in the Phase 2b clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA57 for solid tumors and non-malignant cells of the tumor micro-environment; MDNA109, an IL-2 agonist to treat cancer immunotherapies; MDNA209, an IL-2 antagonist for autoimmune diseases; MDNA413, a dual IL-4/IL-13 antagonist for the treatment of solid tumors, atopic dermatitis, asthma, and fibrosis; and MDNA132, an IL-13 agonist to treat solid tumors and IL 13Ralpha2 chimeric antigen receptor T cell. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

Zacks: Analysts Expect Medicenna Therapeutics Corp. (NASDAQ:MDNA) to Post -$0.07 EPS
May 13, 2021 | americanbankingnews.com

Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer
May 12, 2021 | finance.yahoo.com

Medicenna's MDNA55 Data From Mid-Stage Brain Cancer Study Published In Peer-Reviewed Clinical Cancer Research
May 7, 2021 | finance.yahoo.com

Zacks: Brokerages Anticipate Medicenna Therapeutics Corp. (NASDAQ:MDNA) to Post -$0.07 EPS
April 25, 2021 | americanbankingnews.com

MDNA: Targeting ‘Cold’ Tumors with Dual Cytokine
April 21, 2021 | finance.yahoo.com

Medicenna Therapeutics Announces the Appointment of Industry Veteran, Kevin Moulder, PhD, as Chief Scientific Officer
April 21, 2021 | finance.yahoo.com

Medicenna Presents Preclinical Data Demonstrating Potent Immune Modulating Effects of an IL-2/IL-13 Dual Specific Cytokine at the 2021 AACR Annual Meeting
April 12, 2021 | finance.yahoo.com

MDNA: MDNA11 in Combination with Anti-PD-1 Shows Anti-Tumor Activity in Preclinical Study…
April 8, 2021 | finance.yahoo.com

Medicenna Therapeutics Corp.
March 24, 2021 | barrons.com

Medicenna Therapeutics Announces Upcoming Presentation at the AACR Annual Meeting 2021
March 11, 2021 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:MDNA

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.medicenna.com

Phone416-648-5555

Employees7

Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.77 per share

Price / Book4.43

Profitability

EPS (Most Recent Fiscal Year)($0.19)

Net Income$-6,220,000.00

Net MarginsN/A

Return on Equity-40.19%

Return on Assets-37.66%

Debt

Debt-to-Equity RatioN/A

Current Ratio26.75

Quick Ratio26.75

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Miscellaneous

Outstanding Shares53,548,000

Market Cap$182.60 million

Next Earnings Date5/21/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.70 out of 5 stars

Medical Sector

1296th out of 2,044 stocks

Pharmaceutical Preparations Industry

561st out of 769 stocks

3.5 Analyst's Opinion

Consensus Rating
Medicenna Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.00, Medicenna Therapeutics has a forecasted upside of 193.3% from its current price of $3.41.
Amount of Analyst Coverage
Medicenna Therapeutics has received no research coverage in the past 90 days.

0.0 Community Rank

Outperform Votes
Medicenna Therapeutics has received 0 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Medicenna Therapeutics has received 0 “underperform” votes. (Add your “underperform” vote.)

MarketBeat's community ratings are surveys of what our community members think about Medicenna Therapeutics and other stocks. Vote “Outperform” if you believe MDNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe MDNA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Medicenna Therapeutics does not currently pay a dividend.
Dividend Growth
Medicenna Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Medicenna Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Institutions
Only 3.90% of the stock of Medicenna Therapeutics is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Medicenna Therapeutics are expected to decrease in the coming year, from ($0.19) to ($0.25) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Medicenna Therapeutics is -17.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Medicenna Therapeutics is -17.05, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Medicenna Therapeutics has a P/B Ratio of 4.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Medicenna Therapeutics (NASDAQ:MDNA) Frequently Asked Questions

Is Medicenna Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medicenna Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Medicenna Therapeutics stock.
View analyst ratings for Medicenna Therapeutics or view top-rated stocks.

What stocks does MarketBeat like better than Medicenna Therapeutics?

Wall Street analysts have given Medicenna Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Medicenna Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Medicenna Therapeutics?

Medicenna Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 268,600 shares, an increase of 45.2% from the March 15th total of 185,000 shares. Based on an average daily trading volume, of 218,900 shares, the short-interest ratio is currently 1.2 days. Approximately 0.7% of the shares of the company are sold short.
View Medicenna Therapeutics' Short Interest.

When is Medicenna Therapeutics' next earnings date?

Medicenna Therapeutics is scheduled to release its next quarterly earnings announcement on Friday, May 21st 2021.
View our earnings forecast for Medicenna Therapeutics.

What price target have analysts set for MDNA?

4 brokerages have issued twelve-month target prices for Medicenna Therapeutics' stock. Their forecasts range from $8.00 to $12.00. On average, they anticipate Medicenna Therapeutics' stock price to reach $10.00 in the next year. This suggests a possible upside of 193.3% from the stock's current price.
View analysts' price targets for Medicenna Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Medicenna Therapeutics' key executives?

Medicenna Therapeutics' management team includes the following people:

Dr. Fahar Merchant, Founder, Chairman, CEO & Pres (Age 64, Pay $328.28k)
Ms. Rosemina Merchant, Founder, Chief Devel. Officer & Director (Age 64, Pay $255.51k)
Ms. Elizabeth Williams C.A., CPA, CPA, CA, CFO & Corp. Sec. (Age 43, Pay $179.72k)
Dr. John H. Sampson M.D., Ph.D., MBA, Chief Clinical Advisor
Dr. Martin Bexon M.D., Head of Clinical Devel.
Dr. Samuel R. Denmeade, Scientific Advisor

Who are some of Medicenna Therapeutics' key competitors?

Some companies that are related to Medicenna Therapeutics include ChemoCentryx (CCXI), OrganiGram (OGI), AnaptysBio (ANAB), Xenon Pharmaceuticals (XENE), Chimerix (CMRX), Aldeyra Therapeutics (ALDX), Calliditas Therapeutics AB (publ) (CALT), Karyopharm Therapeutics (KPTI), ZIOPHARM Oncology (ZIOP), Emisphere Technologies (EMIS), Ardelyx (ARDX), Cara Therapeutics (CARA), Gossamer Bio (GOSS), Esperion Therapeutics (ESPR) and IDEAYA Biosciences (IDYA).
View all of MDNA's competitors.

What is Medicenna Therapeutics' stock symbol?

Medicenna Therapeutics trades on the NASDAQ under the ticker symbol "MDNA."

Who are Medicenna Therapeutics' major shareholders?

Medicenna Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Board of Trustees of The Leland Stanford Junior University (1.80%), Renaissance Technologies LLC (0.26%), Geode Capital Management LLC (0.04%) and JPMorgan Chase & Co. (0.02%).

Which major investors are buying Medicenna Therapeutics stock?

MDNA stock was purchased by a variety of institutional investors in the last quarter, including Board of Trustees of The Leland Stanford Junior University, Geode Capital Management LLC, Renaissance Technologies LLC, and JPMorgan Chase & Co..

How do I buy shares of Medicenna Therapeutics?

Shares of MDNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Medicenna Therapeutics' stock price today?

One share of MDNA stock can currently be purchased for approximately $3.41.

How much money does Medicenna Therapeutics make?

Medicenna Therapeutics has a market capitalization of $182.60 million. The company earns $-6,220,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

How many employees does Medicenna Therapeutics have?

Medicenna Therapeutics employs 7 workers across the globe.

What is Medicenna Therapeutics' official website?

The official website for Medicenna Therapeutics is www.medicenna.com.

Where are Medicenna Therapeutics' headquarters?

Medicenna Therapeutics is headquartered at 200-1920 Yonge Street, Toronto A6, M4S 3E2.

How can I contact Medicenna Therapeutics?

Medicenna Therapeutics' mailing address is 200-1920 Yonge Street, Toronto A6, M4S 3E2. The company can be reached via phone at 416-648-5555 or via email at [email protected]

This page was last updated on 5/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here